⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14853562 | 0.70 | — | — | |
| SCHEMBL9754658 | 0.68 | — | — | |
| SCHEMBL9463682 | 0.66 | CRBN (0.39) | — | |
| SCHEMBL2040426 | 0.65 | — | — | |
| SCHEMBL14387952 | 0.62 | — | — | |
| SCHEMBL10053017 | 0.62 | — | — | |
| SCHEMBL162371 | 0.62 | — | — | |
| Ethane SCHEMBL17938755 | 0.60 | CRBN (0.52) | — | |
| SCHEMBL493044 | 0.59 | — | — | |
| SCHEMBL791401 | 0.59 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-5866576-A | COMPOUNDS THAT ACT AS DRUGS ON THE CELLULAR AND BIOCHEMICAL LEVEL TO MODULATE CELLULAR RESPONSES TO NOXIOUS, PRO-INFLAMMATORY STIMULI. | CELL THERAPEUTICS, INC. (US) | 1999-02-02 | — | — | US | claimed |
| EP-0719265-B1 | NUCLEOSIDE DERIVATIVES, METHODS FOR THE MANUFACTURE THEREOF AND SPECIFIC POLYCLONAL AND MONOCLONAL ANTIBODIES OF SAID DERIVATIVES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 1998-12-02 | — | — | EP | claimed |
| US-5801182-A | Amine substituted compounds | CELL THERAPEUTICS, INC. (US) | 1998-09-01 | — | — | US | claimed |
| US-5721341-A | Derivatives of nucleosides, processes for the production of these derivatives of nucleosides and specific polyclonal and monoclonal antibodies of these derivatives | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1998-02-24 | — | — | US | claimed |
| WO-2024135721-A1 | METHOD FOR PRODUCING PRODUCTION INTERMEDIATE, PRODUCTION INTERMEDIATE THEREOF, AND METHOD FOR PRODUCING CROSSLINKED ARTIFICIAL NUCLEIC ACID INTERMEDIATE BY USING SAME | 田辺三菱製薬株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2005004794-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASE | ALNYLAM PHARMACEUTICALS INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-1995020589-A1 | CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 1995-08-03 | — | — | WO | disclosed |